Apyx Medical Corp (APYX) Stock Analysis and Metrics

Apyx Medical

NASDAQ: APYX

$3.94 ▲ +0.11 (+2.77%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap167.53 Mn

P/E-18.27

P/S3.00

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)35.09 Mn

Revenue Growth (1y) (Qtr)32.45

Add ratio to table…

About

Apyx Medical Corporation is a surgical aesthetics company that develops and markets innovative energy based devices for cosmetic and hospital surgical markets. Its core products include the Helium Plasma Platform Technology sold as Renuvion for cosmetic surgery and the hospital surgical system for hospital procedures, as well as the FDA cleared AYON Body Contouring System that combines fat removal, tissue contraction and electrosurgical functions in a single platform. The company focuses on delivering minimally invasive solutions that enable surgeons to achieve precise tissue effects with reduced thermal damage. Its product portfolio is designed to address a range of aesthetic and surgical needs from skin tightening to fat removal and body contouring. The company also generates revenue through original equipment manufacturing agreements, designing and producing electrosurgical generators and accessories for other medical device manufacturers under long term contracts.

Revenue is derived primarily from the sale of Renuvion, the hospital surgical system and AYON systems and their associated single use handpieces and accessories to physicians, cosmetic surgery clinics and surgical centers. In the United States these products are sold through a direct sales force, while internationally the company relies on a distributor network. In 2025 the Surgical Aesthetics segment accounted for approximately 85.8 percent of total revenue while the OEM segment contributed the remaining 14.2 percent. Revenue from consumables such as handpieces and accessories provides a recurring component to the overall sales model. Additionally, the OEM segment contributes revenue by manufacturing and supplying electrosurgical equipment and related components to partners such as Symmetry Surgical under a ten year supply agreement.

The company operates through the following segments: Surgical Aesthetics and OEM.

• Surgical Aesthetics: This segment encompasses the Helium Plasma Technology platforms Renuvion and the hospital surgical system, the AYON Body Contouring System, and related disposable handpieces and accessories, supported by a global sales force, clinical support team, training and marketing initiatives. The segment pursues geographic expansion through regulatory clearances in key markets such as China and Europe, and invests in educational programs to increase surgeon adoption of its technology.

• OEM: This segment focuses on the design, development and manufacture of electrosurgical generators and associated accessories for external medical device manufacturers under long term supply agreements, exemplified by the Manufacturing and Supply Agreement with Symmetry Surgical. The OEM business leverages the company’s expertise in electro surgery to produce components that meet the specifications of larger device makers while maintaining cost effective production.

Apyx Medical Corporation holds a leading niche position in the surgical aesthetics market due to its proprietary helium plasma technology, which is the only FDA cleared device offering controlled heat delivery for tissue contraction and skin tightening. The company’s competitive advantages stem from its long history of innovation, a robust intellectual property portfolio (41 U. S. patents and 61 foreign patents), high product quality backed by ISO 13485 certified manufacturing, and a dedicated global medical affairs team that provides clinical support to surgeons. Key competitors in the broader body contouring space include established liposuction manufacturers such as Solta Medical (a part of Bausch Health Companies, Inc.) and MicroAire Surgical Instruments, although none offer helium based plasma technology. The company believes its focus on surgical solutions provides a competitive edge over non invasive alternatives because surgical procedures tend to deliver more durable and transformative results for patients.

The company’s customers are primarily physicians, cosmetic surgery practices and surgical centers in the United States that purchase Renuvion, the hospital surgical system and AYON systems through its direct sales force. Outside the United States, products are distributed via a network of international distributors serving similar provider segments. The OEM segment serves medical device manufacturers that outsource production of electrosurgical components, with Symmetry Surgical cited as a representative partner. In addition, hospital surgical departments represent a notable customer group for the hospital surgical system, which is used in a variety of operative procedures requiring precise energy delivery.

Investment Thesis

▲ Bull case

Apyx Medical is positioned to capitalize on a significant structural shift in the body contouring market driven by the widespread adoption of GLP-1 medications, which is creating a sustained and growing demand for surgical solutions to address post-weight loss loose and lax skin. The company noted that as of early 2026, roughly one in eight U.S. adults have taken a GLP-1, with projections indicating around 30 million Americans could be using these treatments by 2030, a trend management explicitly linked to increased procedure demand. This demographic shift represents a durable tailwind rather than a temporary trend, as the physiological effects of rapid weight loss necessitate surgical intervention for optimal aesthetic outcomes, directly aligning with Apyx's core offerings of Renuvion and AYON. The early-stage adoption of AYON, combined with its unique value proposition as an all-in-one platform integrating multiple body contouring modalities, allows the company to capture share from both existing Renuvion users seeking upgrades and new customers previously untapped due to procedural complexity or equipment fragmentation. Management highlighted that AYON sales are still in the "top of the first inning," indicating vast runway for growth as the platform gains traction among surgeons prioritizing workflow efficiency, reduced procedure times, and improved patient outcomes—factors increasingly critical in value-based care environments. The anticipated FDA 510 clearance for power liposuction on the AYON platform this quarter is a pivotal, underemphasized catalyst that will eliminate a key adoption barrier for surgeons who exclusively use power-assisted liposuction, thereby expanding the addressable market to include a significant segment of practitioners currently waiting for this functionality before investing in the system. This clearance transforms AYON from a versatile platform into a truly comprehensive solution capable of supporting multiple advanced fat removal techniques on a single console, directly addressing unmet needs in the surgeon community and accelerating both new customer acquisition and upgrade cycles from the established Renuvion base. Furthermore, Apyx's lean operating structure, implemented over the past year, has materially reduced cash burn while maintaining financial flexibility, with $31.1 million in cash as of March 31, 2026, and management expressing confidence in achieving cash flow positivity through 2027 based on AYON uptake and working capital discipline. This financial resilience allows the company to selectively reinvest in high-return initiatives like international expansion and clinical training programs without relying on dilutive financing, a critical advantage in the current macroeconomic environment where many med-tech peers face funding constraints. The international opportunity, particularly in high-growth markets like South Korea where initial demand exceeded expectations post-regulatory approval in December 2025, remains underappreciated by the market; management's plan to pursue AYON registrations across Europe, Latin America, the Middle East, and Asia represents a multi-year growth driver that could meaningfully diversify revenue beyond the U.S. base and mitigate domestic market saturation risks over time.

Apyx Medical is positioned to capitalize on a significant structural shift in the body contouring market driven by the widespread adoption of GLP-1 medications, which is creating a sustained and growing demand for surgical solutions to address post-weight loss loose and lax skin. The company noted that as of early 2026, roughly one in eight U.S. adults have taken a GLP-1, with projections indicating around 30 million Americans could be using these treatments by 2030, a trend management explicitly linked to increased procedure demand. This demographic shift represents a durable tailwind rather than a temporary trend, as the physiological effects of rapid weight loss necessitate surgical intervention for optimal aesthetic outcomes, directly aligning with Apyx's core offerings of Renuvion and AYON. The early-stage adoption of AYON, combined with its unique value proposition as an all-in-one platform integrating multiple body contouring modalities, allows the company to capture share from both existing Renuvion users seeking upgrades and new customers previously untapped due to procedural complexity or equipment fragmentation. Management highlighted that AYON sales are still in the "top of the first inning," indicating vast runway for growth as the platform gains traction among surgeons prioritizing workflow efficiency, reduced procedure times, and improved patient outcomes—factors increasingly critical in value-based care environments. The anticipated FDA 510 clearance for power liposuction on the AYON platform this quarter is a pivotal, underemphasized catalyst that will eliminate a key adoption barrier for surgeons who exclusively use power-assisted liposuction, thereby expanding the addressable market to include a significant segment of practitioners currently waiting for this functionality before investing in the system. This clearance transforms AYON from a versatile platform into a truly comprehensive solution capable of supporting multiple advanced fat removal techniques on a single console, directly addressing unmet needs in the surgeon community and accelerating both new customer acquisition and upgrade cycles from the established Renuvion base. Furthermore, Apyx's lean operating structure, implemented over the past year, has materially reduced cash burn while maintaining financial flexibility, with $31.1 million in cash as of March 31, 2026, and management expressing confidence in achieving cash flow positivity through 2027 based on AYON uptake and working capital discipline. This financial resilience allows the company to selectively reinvest in high-return initiatives like international expansion and clinical training programs without relying on dilutive financing, a critical advantage in the current macroeconomic environment where many med-tech peers face funding constraints. The international opportunity, particularly in high-growth markets like South Korea where initial demand exceeded expectations post-regulatory approval in December 2025, remains underappreciated by the market; management's plan to pursue AYON registrations across Europe, Latin America, the Middle East, and Asia represents a multi-year growth driver that could meaningfully diversify revenue beyond the U.S. base and mitigate domestic market saturation risks over time.

▼ Bear case

Apyx Medical's recent financial performance and strategic outlook mask significant near-term risks rooted in the evolving dynamics of its OEM segment and the potential for macroeconomic headwinds to disproportionately impact discretionary aesthetic procedures, despite management's optimism about GLP-1-driven demand. While Surgical Aesthetics revenue grew 36% year-over-year in Q1 FY26, this growth was partially fueled by a favorable product mix shift that also contributed to an anticipated long-term decline in OEM revenue, which management explicitly stated will decrease for the full year and continue to trend downward over time—a structural shift that could undermine the company's historical revenue stability and cash flow generation from its higher-margin OEM business. The OEM segment, which contributed approximately $7.5 million in revenue for FY25, is now guided to approximately $5 million for FY26, representing a 33% decline that offsets gains in Surgical Aesthetics and highlights the risk of cannibalization or strategic misalignment as the company pivots focus toward its newer, less proven AYON platform. This decline raises concerns about whether the gross margin expansion seen in Q1 FY26 (up to 63.5% from 60.1%) is sustainable, as management attributed part of the improvement to segment mix rather than pure operational efficiency, and warned that increasing international sales—while beneficial for top-line growth—come with geographic mix headwinds and ongoing tariff impacts that could erode margins if not fully mitigated by dual manufacturing in Bulgaria and Florida. Furthermore, despite management's dismissal of tariff impacts as minimized, the acknowledgment that tariffs began affecting the business in the second half of 2025 and remain factored into guidance suggests vulnerability to trade policy volatility, especially if protections for U.S.-manufactured components change or if international sales growth remains dependent on cost structures sensitive to duty fluctuations. The company's reliance on the GLP-1 trend as a demand catalyst also presents a bearish counterargument: while patient interest in loose skin solutions is rising, aesthetic procedures remain discretionary and highly sensitive to consumer confidence, unemployment rates, and access to financing—factors that could deteriorate rapidly in an economic downturn, leaving Apyx exposed to a sharp reversal in procedure volumes even if the underlying patient need persists. Additionally, the commercial rollout of AYON, while framed as early-stage, faces adoption risks beyond the waiting-for-power-lipo segment; management conceded that only about 80% of AYON sales to date have been to existing Renuvion customers, meaning the pipeline of new customer acquisition is still unproven at scale, and the claimed benefits of reduced procedure times and improved outcomes remain largely anecdotal, lacking robust, widely published clinical data that could accelerate broad surgeon adoption. Finally, the company's guidance assumes gross margins of 62% to 63% for the full year, a range that leaves little room for error given the combination of tariff exposure, international mix shifts, and the need to fund AYON commercialization efforts—any margin pressure from these factors could quickly push the business back into sustained cash burn, challenging management's assertion of cash flow positivity through 2027 and potentially necessitating dilutive capital raises at unfavorable terms.

Apyx Medical's recent financial performance and strategic outlook mask significant near-term risks rooted in the evolving dynamics of its OEM segment and the potential for macroeconomic headwinds to disproportionately impact discretionary aesthetic procedures, despite management's optimism about GLP-1-driven demand. While Surgical Aesthetics revenue grew 36% year-over-year in Q1 FY26, this growth was partially fueled by a favorable product mix shift that also contributed to an anticipated long-term decline in OEM revenue, which management explicitly stated will decrease for the full year and continue to trend downward over time—a structural shift that could undermine the company's historical revenue stability and cash flow generation from its higher-margin OEM business. The OEM segment, which contributed approximately $7.5 million in revenue for FY25, is now guided to approximately $5 million for FY26, representing a 33% decline that offsets gains in Surgical Aesthetics and highlights the risk of cannibalization or strategic misalignment as the company pivots focus toward its newer, less proven AYON platform. This decline raises concerns about whether the gross margin expansion seen in Q1 FY26 (up to 63.5% from 60.1%) is sustainable, as management attributed part of the improvement to segment mix rather than pure operational efficiency, and warned that increasing international sales—while beneficial for top-line growth—come with geographic mix headwinds and ongoing tariff impacts that could erode margins if not fully mitigated by dual manufacturing in Bulgaria and Florida. Furthermore, despite management's dismissal of tariff impacts as minimized, the acknowledgment that tariffs began affecting the business in the second half of 2025 and remain factored into guidance suggests vulnerability to trade policy volatility, especially if protections for U.S.-manufactured components change or if international sales growth remains dependent on cost structures sensitive to duty fluctuations. The company's reliance on the GLP-1 trend as a demand catalyst also presents a bearish counterargument: while patient interest in loose skin solutions is rising, aesthetic procedures remain discretionary and highly sensitive to consumer confidence, unemployment rates, and access to financing—factors that could deteriorate rapidly in an economic downturn, leaving Apyx exposed to a sharp reversal in procedure volumes even if the underlying patient need persists. Additionally, the commercial rollout of AYON, while framed as early-stage, faces adoption risks beyond the waiting-for-power-lipo segment; management conceded that only about 80% of AYON sales to date have been to existing Renuvion customers, meaning the pipeline of new customer acquisition is still unproven at scale, and the claimed benefits of reduced procedure times and improved outcomes remain largely anecdotal, lacking robust, widely published clinical data that could accelerate broad surgeon adoption. Finally, the company's guidance assumes gross margins of 62% to 63% for the full year, a range that leaves little room for error given the combination of tariff exposure, international mix shifts, and the need to fund AYON commercialization efforts—any margin pressure from these factors could quickly push the business back into sustained cash burn, challenging management's assertion of cash flow positivity through 2027 and potentially necessitating dilutive capital raises at unfavorable terms.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password